Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (Nasdaq: NBTX) reported its share capital and voting rights as of May 31, 2026, in line with French market regulations.
The company had 50,807,903 shares outstanding, with 54,304,858 theoretical and 54,282,740 exercisable voting rights on Euronext Paris and Nasdaq.
Positive
- None.
Negative
- None.
News Market Reaction – NBTX
On the day this news was published, NBTX declined 1.80%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Ops/financial update | Positive | -4.2% | Q1 2026 operational and financial progress, including cash runway into 2029. |
| Jun 02 | Index inclusion | Positive | -3.3% | Addition to Euronext Tech Leaders segment and index to boost visibility. |
| May 26 | Global offering close | Positive | -0.7% | Closing of global offering raising about $100M in gross proceeds. |
| May 22 | Over-allotment exercise | Positive | -0.5% | Full exercise of over-allotment option, lifting offering gross proceeds to ~$100M. |
| May 21 | Offering pricing | Positive | -6.9% | Pricing of oversubscribed €85m global follow-on equity offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the last five news events, NBTX showed negative 24h price reactions to operational updates, index inclusion, and equity offerings.
Over recent months, Nanobiotix reported a global equity offering raising about $100 million, multiple follow-on and over-allotment details, and an oversubscribed €85m financing, all intended to fund operations into 2029. It also provided a Q1 2026 operational and financial update and was added to the Euronext Tech Leaders Index. Despite generally constructive corporate developments, each of these announcements saw a negative 24-hour price reaction, highlighting a pattern of cautious market responses to both financing and operational news.
Key Terms
voting rights regulatory
isin code regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, June 05, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| May 31, 2026 | 50,807,903 | 54,304,858 | 54,282,740 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
_______________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2026-06-05 -- NBTX -- Voting Rights & Shares Capital -- FINAL
